Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.
Acrylamides
/ adverse effects
Aged
Aniline Compounds
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
ErbB Receptors
/ genetics
Humans
Lung Neoplasms
/ drug therapy
Mutation
Pneumonia
/ chemically induced
Protein Kinase Inhibitors
/ adverse effects
Treatment Outcome
Epithelial growth factor receptor
interstitial lung disease
pneumonitis
side effect
tyrosine kinase inhibitor
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
03
2020
accepted:
20
04
2020
pubmed:
7
5
2020
medline:
12
3
2021
entrez:
7
5
2020
Statut:
ppublish
Résumé
Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR-mutated non-small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority of patients, severe and even life-threatening side effects have been reported. TKI-induced interstitial lung disease (ILD) has been reported for single cases in modest severity, predominantly in EGFR-TKI pretreated patients. Here, we report a case of successful stabilization of a life-threatening ILD in a de novo T790M mutated NSCLC during first-line treatment with osimertinib. As osimertinib will be used more often in many EGFR-positive NSCLC patients in the future, this potentially life-threatening side effect should receive special attention, especially in first-line treatment.
Identifiants
pubmed: 32374485
doi: 10.1111/1759-7714.13476
pmc: PMC7327687
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Protein Kinase Inhibitors
0
osimertinib
3C06JJ0Z2O
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2044-2047Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Lung Cancer. 2018 Sep;123:60-69
pubmed: 30089596
JAMA Oncol. 2018 Aug 1;4(8):1112-1115
pubmed: 29327061
Int J Clin Pharmacol Ther. 2011 Jul;49(7):461-6
pubmed: 21726497
Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36
pubmed: 30508196
Jpn J Clin Oncol. 2017 Jul 1;47(7):625-629
pubmed: 28419328
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
PLoS One. 2019 Jan 9;14(1):e0210225
pubmed: 30625213
Invest New Drugs. 2017 Feb;35(1):105-107
pubmed: 27599705
Int J Cancer. 2019 Jul 1;145(1):284-294
pubmed: 30613959
Korean J Fam Med. 2016 Nov;37(6):351-355
pubmed: 27900074
Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248
pubmed: 30457891
J Thorac Oncol. 2018 Aug;13(8):1106-1112
pubmed: 29775809
J Thorac Oncol. 2017 Apr;12(4):633-643
pubmed: 28007626
Mol Clin Oncol. 2017 Sep;7(3):383-385
pubmed: 28808573
Chin Med J (Engl). 2016 Jun 20;129(12):1507-8
pubmed: 27270553
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012